Search hospitals > California > Roseville
Sutter Roseville Medical Center
Claim this profileRoseville, California 95661
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
174 reported clinical trials
9 medical researchers
Summary
Sutter Roseville Medical Center is a medical facility located in Roseville, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Roseville Medical Center is involved with conducting 174 clinical trials across 339 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus7 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
28 reported clinical trials
66 drugs studied
Christopher JonesSutter Medical Center Sacramento3 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
23 reported clinical trials
62 drugs studied
Deepti BehlCalifornia Pacific Medical Center-Pacific Campus4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
49 drugs studied
Kristie A. BobolisAlta Bates Summit Medical Center-Herrick Campus1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
27 drugs studied
Clinical Trials running at Sutter Roseville Medical Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Melanoma
Squamous Cell Carcinoma
Pancreatic Cancer
Renal Cell Carcinoma
Multiple Myeloma
Ovarian Cancer
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Sutter Roseville Medical Center?
Sutter Roseville Medical Center is a medical facility located in Roseville, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Roseville Medical Center is involved with conducting 174 clinical trials across 339 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.